ADEL, Inc.

Based in South Korea, ADEL, Inc. specializes in developing innovative therapeutic antibodies aimed at treating neurodegenerative diseases, particularly Alzheimer's disease, enhancing patient care through advanced biopharmaceutical solutions. Founded in 2016, ADEL, Inc. operates from its headquarters in Seoul, South Korea.

The company focuses on the development of therapeutic antibodies targeting neurodegenerative diseases. It has engaged in four total funding deals, with the latest being a Pre-IPO round that raised KRW 49 billion on April 9, 2026, backed by notable investors such as Korea Investment Partners and Samsung Venture Investment. The current CEO is Seung-yong Yoon, who leads the company in its mission to advance therapeutic innovations. ADEL, Inc.

specializes in the development of innovative therapeutic antibodies aimed at treating neurodegenerative diseases, particularly Alzheimer's disease. The company's core product offerings include monoclonal antibodies like Tau-acK280, β2-microglobulin, and ApoE4, which target protein aggregates linked to Alzheimer's pathology. Their proprietary technologies, including the Autophagic Degradation Targeting Chimera (ADTAC™) and Brain Targeting System (BTS), enhance the delivery and effectiveness of these therapies, primarily serving pharmaceutical companies and research institutions in North America and Asia. ADEL, Inc.

generates revenue through direct product sales and collaborations with research institutions and pharmaceutical companies. The business model is based on B2B transactions, licensing proprietary technologies and therapeutic products for clinical trials and drug development. Revenue stems from flagship products such as the Tau-acK280 and β2-microglobulin antibodies, which are procured through bulk orders or subscription agreements, as the company focuses on expanding its market reach in neurodegenerative diseases. In April 2026, ADEL, Inc.

raised KRW 49 billion in Pre-IPO funding to support the preclinical development of its CNS antibody programs, specifically ADEL-Y04 and ADEL-Y03. The company plans to expand into new markets, particularly targeting North America and Europe, by 2027. This funding will bolster their capabilities in developing new therapeutic products and enhance ongoing research to address unmet medical needs in neurodegenerative diseases.